Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics reports clinical, financial and governance developments for a late-stage biotechnology company developing disease-targeted gene therapy product candidates. Its recurring updates center on 4D-150 for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, and on clinical programs such as 4FRONT, PRISM and SPECTRA.
Company news also covers quarterly and annual financial results, cash runway commentary, collaboration and license revenue tied to Otsuka, investor conference participation, board and leadership changes, and employment inducement equity grants. The company states that its product candidates remain in clinical or preclinical development and have not been approved for marketing by the FDA or other regulatory authorities.
4D Molecular Therapeutics (NASDAQ:FDMT) reported Q2 2025 financial results and operational updates, highlighting significant progress in its clinical programs. The company announced an accelerated timeline for its 4D-150 Phase 3 program in wet AMD, with 4FRONT-1 data now expected in H1 2027. Additionally, positive 60-week results were presented from the 4D-150 SPECTRA trial in DME.
Key financial metrics include $417 million in cash as of June 30, 2025, expected to fund operations into 2028. Q2 2025 saw R&D expenses of $48.0 million and a net loss of $54.7 million. The company implemented a 25% workforce reduction, expected to generate annual savings of $15 million.
Clinical progress includes strong enrollment in the 4FRONT-1 trial, early initiation of 4FRONT-2, and positive DME trial results showing favorable tolerability and sustained durability. Both FDA and EMA indicated that a single successful Phase 3 study could support approval in the U.S. and Europe.
4D Molecular Therapeutics (NASDAQ:FDMT), a late-stage biotechnology company, announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. The company's management will engage in a fireside chat on Wednesday, August 13, 2025, at 2:30 p.m. ET.
The presentation will be available via webcast, and management will be available for one-on-one meetings. An archived recording of the webcast will be accessible for up to one year on the company's investor relations website.
4D Molecular Therapeutics (NASDAQ:FDMT) announced positive 60-week results from the SPECTRA clinical trial evaluating 4D-150 in diabetic macular edema (DME) patients. The Phase 3 dose (3E10 vg/eye) demonstrated significant efficacy with a 78% reduction in treatment burden compared to projected aflibercept treatment.
Key results include sustained visual acuity gains of +9.7 letters and anatomic improvement with CST reduction of -174 µm. The treatment was well-tolerated with no intraocular inflammation observed. Notably, patients receiving the Phase 3 dose required only 1.6 mean supplemental injections compared to 3.7 for lower doses and 7.0 projected for aflibercept.
Both FDA and EMA have aligned that a single Phase 3 clinical trial would be acceptable for regulatory submission for 4D-150 in DME, streamlining the path to potential approval.
4D Molecular Therapeutics (NASDAQ:FDMT) announced two upcoming presentations at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Long Beach, CA, from July 30 – August 2, 2025.
The presentations will feature interim results from two clinical trials: the SPECTRA Phase 2a trial evaluating 4D-150 for Diabetic Macular Edema, including 52-week primary endpoint and 60-week analyses, and the PRISM Phase 2b trial evaluating 4D-150 for neovascular Age-related Macular Degeneration with 52-week results. Both presentations will be available on the company's website.
4D Molecular Therapeutics (Nasdaq: FDMT), a late-stage biotechnology company, has granted 4,600 Restricted Stock Units (RSUs) to one new non-executive employee on July 8, 2025. The RSUs were awarded under the Company's 2025 Employment Inducement Award Plan, which was established in February 2025 in accordance with Nasdaq Global Market Rule 5635(c)(4) to incentivize new employee recruitment.
4D Molecular Therapeutics (NASDAQ:FDMT) announced significant acceleration of its 4D-150 Phase 3 program for wet age-related macular degeneration (wet AMD). The 4FRONT-1 Phase 3 trial's topline data readout has been moved forward to H1 2027 from H2 2027, while the 4FRONT-2 Phase 3 trial was initiated ahead of schedule in June 2025.
The company implemented a 25% workforce reduction, primarily affecting early-stage R&D and support functions, expected to generate $15 million in annual cash savings. With $458 million in cash as of March 31, 2025, FDMT maintains its cash runway into 2028, supporting both Phase 3 trials, BLA preparation, and ongoing development programs in diabetic macular edema and cystic fibrosis.
4D Molecular Therapeutics (FDMT), a late-stage biotechnology company, has announced its participation in two major upcoming investor conferences in June 2025. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4 at 3:45 p.m. ET and the Goldman Sachs Global Healthcare Conference on June 11 at 11:20 a.m. ET. One-on-one meetings with management will be available, and webcasts of the presentations will be accessible for up to one year on the company's investor relations website.
4D Molecular Therapeutics (FDMT) reported Q1 2025 financial results and key operational updates. The company has enrolled first patients in its 4D-150 Phase 3 clinical trial (4FRONT-1) for wet AMD, with over 50 clinical sites active. A second Phase 3 trial (4FRONT-2) is expected to begin in Q3 2025, with topline data from both trials anticipated in H2 2027.
The company maintains a strong financial position with $458 million in cash and equivalents as of March 31, 2025, expected to fund operations into 2028. Q1 2025 saw a net loss of $48.0 million, with R&D expenses of $40.7 million and G&A expenses of $12.9 million.
Notable achievements include receiving RMAT designation for 4D-150 in DME and positive Phase 1/2 trial results showing an 83% reduction in injection burden for wet AMD patients. The company has focused its pipeline on core programs 4D-150 and 4D-710, while pausing several other programs to extend cash runway.
4D Molecular Therapeutics (FDMT), a late-stage biotechnology company, has announced its participation in two major healthcare investor conferences in May 2025. The company's management will engage in fireside chats at the BofA Securities 2025 Healthcare Conference on May 14 at 2:20 p.m. PT and the RBC Capital Markets 2025 Global Healthcare Conference on May 21 at 9:00 a.m. ET. Management will also be available for one-on-one meetings with investors. Webcasts of both presentations will be accessible through the company's investor relations website for up to one year.